Rhythm Control in AF: Have We Reached the Last Frontier?

Area of Science:

• Cardiology
• Public Health
• Pharmacology

Background:

• Atrial fibrillation (AF) is a worldwide epidemic affecting 33 million people, increasing healthcare costs.
• AF significantly elevates the risk of myocardial infarction, heart failure, stroke, dementia, chronic kidney disease, and mortality.
• Maintaining sinus rhythm is crucial for improved patient outcomes.

Purpose of the Study:

• To highlight the limitations of current pharmacological and interventional therapies for AF rhythm control.
• To emphasize the need for novel therapeutic targets and treatments for AF.
• To bridge the gap between existing rhythm control strategies and future expectations.

Main Methods:

• Review of current pharmacological antiarrhythmic drug therapy and its limitations (efficacy, safety, toxicity).
• Assessment of the development and impact of ablation techniques on hard endpoints.
• Exploration of the complex mechanisms underlying AF to identify new therapeutic targets.

Main Results:

• Current antiarrhythmic drugs have limited efficacy and safety due to empirical use, proarrhythmic risks, and organ toxicity.
• AF ablation has not yet demonstrated a significant impact on hard clinical endpoints.
• Understanding AF mechanisms is key to developing novel, targeted therapies.

Conclusions:

• Existing treatments for AF rhythm control are insufficient, necessitating new approaches.
• Further research into AF pathophysiology is vital for developing innovative therapeutic molecules.
• Future therapies aim to improve upon current treatments for maintaining sinus rhythm and managing AF.